Peptide research profile
Retatrutide
Also known as LY3437943 · reta
A randomized phase 2 trial in 338 adults showed dose-dependent weight reduction over 48 weeks. Phase 3 development is intended to determine whether the benefits, risks, and durability hold in larger populations.
Moderate evidenceInvestigational
- Evidence maturity
- Developing record
- Regulatory status
- Investigational
- Recorded outcomes
- 3
- Indexed sources
- 2
- Side-effect records
- 270Named most often: Anhedonia · Fatigue · Nausea
Educational. Not medical advice.
Summary
An investigational triple-receptor agonist with promising phase 2 weight-loss results but no FDA approval.
What is Retatrutide being studied for?
Investigational weight-management therapy
How is it thought to work?
Activates GIP, GLP-1, and glucagon receptors, combining appetite and metabolic signaling pathways.
Recorded outcomes
270 side-effect records on Retatrutide
Free account3 graded outcomes and 2 sources for Retatrutide.
Outcome table and every source open with a free account. No card.
Update history
Updated
- Editorial review of the profile and its sources.
- Record last updated in the Senzu database.
- Profile first published.